

National Board of Examinations

Question Paper Name : DNB Pharmacology Paper3
Subject Name : DNB Pharmacology Paper3
Duration : 180
Total Marks : 100
Display Marks: No

Maximum Instruction Time : 0

Question Number : 1 Question Id : 32718733034 Consider As Subjective : Yes

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. Discuss the aims, methodology and limitations of acute toxicity studies done on animals. [3+5+2]

Question Number : 2 Question Id : 32718733035 Consider As Subjective : Yes

What is Randomized Controlled Trial (RCT)? Describe its usefulness and limitations in clinical research. [4+(3+3)]

Question Number : 3 Question Id : 32718733036 Consider As Subjective : Yes

Discuss the concept of reverse pharmacology and its importance. [10]

Question Number : 4 Question Id : 32718733037 Consider As Subjective : Yes

Critically comment and compare research article, systematic review and meta-analysis. [10]

Question Number : 5 Question Id : 32718733038 Consider As Subjective : Yes

Describe pre-clinical models for evaluation of anti-cancer drugs. [10]

Question Number : 6 Question Id : 32718733039 Consider As Subjective : Yes

Explain in brief the differences between statistical and clinical significance. [10]

Question Number : 7 Question Id : 32718733040 Consider As Subjective : Yes

Make a comparative evaluation of CCSEA and ARRIVE guidelines for animal experimentations. [10]

Question Number : 8 Question Id : 32718733041 Consider As Subjective : Yes

What is an academic clinical trial? What are the differences with respect to industry sponsored clinical trials? [10]

Question Number : 9 Question Id : 32718733042 Consider As Subjective : Yes

What are rare diseases. Give suitable examples. Briefly discuss the drugs for rare disease along with a note on the development process. [10]

Question Number : 10 Question Id : 32718733043 Consider As Subjective : Yes

Discuss the screening methods for evaluation of anti-tubercular agents. [10]